Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Myriad Genetics (MYGN) EBIAT (2016 - 2025)

Myriad Genetics (MYGN) has disclosed EBIAT for 17 consecutive years, with -$7.9 million as the latest value for Q4 2025.

  • Quarterly EBIAT rose 81.41% to -$7.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$365.9 million through Dec 2025, down 187.43% year-over-year, with the annual reading at -$365.9 million for FY2025, 187.43% down from the prior year.
  • EBIAT for Q4 2025 was -$7.9 million at Myriad Genetics, up from -$27.4 million in the prior quarter.
  • The five-year high for EBIAT was $24.6 million in Q3 2021, with the low at -$330.5 million in Q2 2025.
  • Average EBIAT over 5 years is -$44.8 million, with a median of -$29.3 million recorded in 2023.
  • The sharpest move saw EBIAT skyrocketed 261.84% in 2021, then plummeted 800.54% in 2025.
  • Over 5 years, EBIAT stood at -$7.6 million in 2021, then crashed by 456.58% to -$42.3 million in 2022, then increased by 26.24% to -$31.2 million in 2023, then plummeted by 36.22% to -$42.5 million in 2024, then surged by 81.41% to -$7.9 million in 2025.
  • According to Business Quant data, EBIAT over the past three periods came in at -$7.9 million, -$27.4 million, and -$330.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.